Marker Therapeutics, Inc.

Tagged: TPIV 200

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).

Read More

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.

Read More

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

TapImmune, Inc. (NASDAQ: TPIV), today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients.

Read More

TapImmune Enters into Definitive Agreements to raise $8.5 Million from the Exercise of Outstanding Warrants and in a Private Placement from New Investors

…Company has Applied for Listing on Nasdaq Capital Market

JACKSONVILLE, Florida, August 11, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today the entry into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million.

Read More

TapImmune Doses First Patient in its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

…Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

JACKSONVILLE, FL, June 21, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced reaching a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200.

Read More

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

…Doses for use at Mayo Clinic and other clinical sites

Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, its multi-epitope folate receptor peptide vaccine for breast and ovarian cancer.

Read More